SCM
KRYS icon

Soleus Capital Management’s Krystal Biotech KRYS Stock Holding History

Soleus Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349M Sell
939,254
-213,833
-19% -$63.9M 12.03% 1
2026
Q1 		$298M Buy
1,153,087
+212,028
+23% +$56.4M 12.06% 1
2025
Q4 		$232M Sell
941,059
-77,772
-8% -$16.4M 8.56% 2
2025
Q3 		$180M Buy
1,018,831
+95,873
+10% +$14.4M 9.05% 1
2025
Q2 		$127M Buy
922,958
+481,200
+109% +$70.7M 8.4% 1
2025
Q1 		$79.6M Buy
441,758
+83,379
+23% +$14M 5.73% 4
2024
Q4 		$56.1M Buy
358,379
+141,400
+65% +$25.1M 3.53% 5
2024
Q3 		$39.5M Buy
216,979
+90,979
+72% +$17.5M 3.06% 7
2024
Q2 		$23.1M Buy
126,000
+41,900
+50% +$7.03M 2.04% 13
2024
Q1 		$15M Buy
84,100
+44,100
+110% +$6.13M 1.11% 28
2023
Q4 		$4.96M Sell
40,000
-77,892
-66% -$8.64M 0.55% 44
2023
Q3 		$13.7M Buy
117,892
+7,700
+7% +$939K 1.26% 26
2023
Q2 		$12.9M Buy
110,192
+25,013
+29% +$2.55M 1.44% 20
2023
Q1 		$6.82M Sell
85,179
-103,038
-55% -$8.09M 0.71% 40
2022
Q4 		$14.9M Sell
188,217
-19,115
-9% -$1.42M 2.14% 14
2022
Q3 		$14.5M Sell
207,332
-7,150
-3% -$517K 1.96% 17
2022
Q2 		$14.1M Sell
214,482
-74,855
-26% -$4.66M 2.2% 12
2022
Q1 		$19.3M Buy
289,337
+60,900
+27% +$3.8M 2.48% 11
2021
Q4 		$16M Buy
228,437
+102,908
+82% +$5.99M 1.6% 23
2021
Q3 		$6.55M Buy
125,529
+58,000
+86% +$3.43M 1.02% 29
2021
Q2 		$4.59M Sell
67,529
-99,315
-60% -$6.93M 0.71% 29
2021
Q1 		$12.9M Buy
166,844
+156,421
+1,501% +$11.4M 2.32% 7
2020
Q4 		$625K Buy
+10,423
New +$521K 0.08% 59

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Soleus Capital Management's KRYS Position: Q2 2026 in Review

Soleus Capital Management reduced its Krystal Biotech (KRYS) stake by 19% in Q2 2026, selling an estimated $63.9M and leaving 939,254 shares worth $349M. The position accounts for 12.03% of the portfolio, ranked #1.

Soleus Capital Management first reported a position in KRYS in Q4 2020 and has held it in 23 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Soleus Capital Management held 939,254 shares of Krystal Biotech worth $349M as of Q2 2026.
  • Soleus Capital Management sold 213,833 Krystal Biotech shares in Q2 2026, an estimated $63.9M.
  • Krystal Biotech made up 12.03% of Soleus Capital Management's portfolio in Q2 2026, its #1 holding.
  • Soleus Capital Management first reported a position in Krystal Biotech in Q4 2020 and has held it in 23 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.